BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35093316)

  • 1. A targeted expression panel for classification, gene fusion detection and PD-L1 measurements - Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?
    Simonsen AT; Utke A; Lade-Keller J; Thomsen LW; Steiniche T; Stougaard M
    Exp Mol Pathol; 2022 Apr; 125():104749. PubMed ID: 35093316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
    Vannitamby A; Hendry S; Irving L; Steinfort D; Bozinovski S
    Lung Cancer; 2019 Aug; 134():233-237. PubMed ID: 31319986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological features of patients with RET fusion-positive non-small cell lung cancer].
    Tan Q; Ji Y; Wang XL; Wang ZW; Qi XW; Liu YK
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):124-128. PubMed ID: 36748131
    [No Abstract]   [Full Text] [Related]  

  • 8. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
    Cai L; Duan J; Qian L; Wang Z; Wang S; Li S; Wang C; Zhao J; Zhang X; Bai H; Wang J
    Front Immunol; 2020; 11():527750. PubMed ID: 33324391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
    Liu Z; Zhao K; Wei S; Liu C; Zhou J; Gou Q; Wu X; Yang Z; Yang Y; Peng Y; Cheng Q; Liu L
    Oncoimmunology; 2020 May; 9(1):1758003. PubMed ID: 32923114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
    Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
    Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.
    Pisapia P; Iaccarino A; De Luca C; Acanfora G; Bellevicine C; Bianco R; Daniele B; Ciampi L; De Felice M; Fabozzi T; Formisano L; Giordano P; Gridelli C; Ianniello GP; Libroia A; Maione P; Nacchio M; Pagni F; Palmieri G; Pepe F; Russo G; Salatiello M; Santaniello A; Scamarcio R; Seminati D; Troia M; Troncone G; Vigliar E; Malapelle U
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
    Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Ilie M; Beaulande M; Hamila M; Erb G; Hofman V; Hofman P
    Lung Cancer; 2018 Oct; 124():90-94. PubMed ID: 30268486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.